Company: MYGN
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0000899923-25-000028
Chunk: 43

Company: MYRIAD GENETICS INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 43
---
 Officer, effective April 30, 2024. He previously served as President, Mental Health or President, Myriad Neuroscience from August 2017 to April 2022, and as President of Myriad Autoimmune from May 2020 until the sale of the Myriad Autoimmune business in September 2021. Prior to his appointment as President, Myriad Neuroscience, he served as SVP, Chief Sales and Business Development officer at Assurex since January 2016. 
 Mr. Verratti also held senior leadership positions worldwide with Cyberonics (now known as LivaNova) from 2005-2016, and earlier with Forest Pharmaceuticals where he led commercial teams with revenues approaching $500 million dollars. He received a B.S. in Life Sciences with a minor in Physiology from The Pennsylvania State University.                                                                                                                                                                                                                                               |     |                          |
| Age:56                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |     |                          |

27

We have entered into standard employment agreements with each of the above executive officers. For each such officer, we have also entered into our standard Severance and Change of Control Agreements, which are described elsewhere in the proxy statement under the caption ‘‘Executive and Director Compensation—Potential Payments Upon Termination or Change of Control.’’ Sustainability and Corporate Responsibility

Sustainability As part of our mission of advancing the health and well-being of others, we strive to conduct our business in a sustainable and environmentally responsible manner. Some of our environmental initiatives include: • Led by our Green Team, we have recycled approximately 150.5 tons of plastics in our Salt Lake City laboratory since our recycling program started in 2019, including 23.6 tons of plastic during fiscal year 2024. • We completed our carbon inventory, measuring our Scope 1 and Scope 2 emissions from the use of our laboratories and office spaces during the year ended December 31, 2023. Energy and emissions data was captured for select buildings with the largest footprint and used to model emissions from our remaining operations where limited or no data was available. • Our new laboratories in west Salt Lake City, Utah and South San Francisco, California include energy and water efficiency and other environmental-friendly features. The new laboratory facilities help us increase our operational capacity while allowing us to reduce the overall size of our facilities footprint. The new laboratories are equipped with automated liquid handling and waste treatment capabilities, which we expect will reduce plastic waste and create more environmentally sustainable laboratories. Human Capital Management We believe the success of our mission depends, in part, on